Furthermore, Negrao and colleagues (2023) recently published the first prospective data for the KRAS G12C inhibitor adagrasib in patients with NSCLC and radiologically evaluable, active, and untreated CNS metastases (57). This evidence concerns the gene KRAS and non-small cell lung carcinoma.